List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2707954/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. New England Journal of Medicine, 2018, 379, 1905-1914.	27.0	527
2	Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2210-2219.	7.1	173
3	The burden of sepsis-associated mortality in the United States from 1999 to 2005: an analysis of multiple-cause-of-death data. Critical Care, 2009, 13, R28.	5.8	171
4	Associations Between Built Environment, Neighborhood Socioeconomic Status, and SARS-CoV-2 Infection Among Pregnant Women in New York City. JAMA - Journal of the American Medical Association, 2020, 324, 390.	7.4	144
5	Cryopreserved embryo transfer isÂanÂindependent risk factor forÂplacenta accreta. Fertility and Sterility, 2015, 103, 1176-1184.e2.	1.0	129
6	Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical Cancer. JAMA Oncology, 2020, 6, 1019.	7.1	124
7	Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical Procedures. Annals of Surgery, 2021, 273, 34-40.	4.2	120
8	Trends in the use of neoadjuvant chemotherapy for advanced ovarian cancer in the United States. Gynecologic Oncology, 2016, 143, 236-240.	1.4	97
9	Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2017, 129, 439-447.	2.4	95
10	Minimally Invasive Radical Hysterectomy for Cervical Cancer Is Associated With Reduced Morbidity and Similar Survival Outcomes Compared With Laparotomy. Journal of Minimally Invasive Gynecology, 2017, 24, 402-406.	0.6	79
11	Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer. JAMA Oncology, 2017, 3, 76.	7.1	77
12	Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies. Gynecologic Oncology, 2018, 149, 4-11.	1.4	66
13	Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: Does early diagnosis alter risk for gestational trophoblastic neoplasia?. Gynecologic Oncology, 2015, 138, 46-49.	1.4	64
14	Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception, 2010, 82, 491-496.	1.5	62
15	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer. Obstetrics and Gynecology, 2016, 128, 761-770.	2.4	56
16	Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy. Obstetrics and Gynecology, 2017, 129, 861-869.	2.4	55
17	Use and Misuse of Opioids After Gynecologic Surgical Procedures. Obstetrics and Gynecology, 2019, 134, 250-260.	2.4	46
18	Egg banking in the United States: current status of commercially available cryopreserved oocytes. Fertility and Sterility, 2013, 99, 827-831.	1.0	44

#	Article	IF	CITATIONS
19	Same-Day Discharge After Laparoscopic Hysterectomy for Endometrial Cancer. Annals of Surgical Oncology, 2016, 23, 178-185.	1.5	44
20	Laparoscopic staging for apparent stage I epithelial ovarianÂcancer. American Journal of Obstetrics and Gynecology, 2017, 216, 50.e1-50.e12.	1.3	43
21	All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2017, 130, 71-79.	2.4	42
22	Influence of Race and Ethnicity on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Rates and Clinical Outcomes in Pregnancy. Obstetrics and Gynecology, 2020, 136, 1040-1043.	2.4	39
23	Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system. Contraception, 2013, 87, 426-431.	1.5	35
24	Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecologic Oncology, 2019, 154, 595-601.	1.4	35
25	Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades. International Journal of Gynecological Cancer, 2016, 26, 367-370.	2.5	33
26	The effect of adolescence and advanced maternal age on the incidence of complete and partial molar pregnancy. Gynecologic Oncology, 2016, 140, 470-473.	1.4	33
27	Associations between residual disease and survival in epithelial ovarian cancer by histologic type. Gynecologic Oncology, 2017, 147, 250-256.	1.4	33
28	Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE). International Journal of Gynecological Cancer, 2020, 30, 1450-1454.	2.5	33
29	Minimally Invasive Staging Surgery in Women with Early-Stage Endometrial Cancer: Analysis of the National Cancer Data Base. Annals of Surgical Oncology, 2017, 24, 1677-1687.	1.5	32
30	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2017, 129, 139-151.	2.4	31
31	Trends in Primary Treatment and Median Survival Among Women With Advanced-Stage Epithelial Ovarian Cancer in the US From 2004 to 2016. JAMA Network Open, 2020, 3, e2017517.	5.9	31
32	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. American Journal of Obstetrics and Gynecology, 2019, 220, 469.e1-469.e13.	1.3	30
33	Impact of quality of care on racial disparities in survival for endometrial cancer. American Journal of Obstetrics and Gynecology, 2020, 223, 396.e1-396.e13.	1.3	30
34	Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarianAcancer. American Journal of Obstetrics and Gynecology, 2019, 220, 571.e1-571.e8.	1.3	29
35	Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study. BMJ: British Medical Journal, 2018, 360, j5463.	2.3	27
36	Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecologic Oncology, 2021, 161, 653-659.	1.4	26

#	Article	IF	CITATIONS
37	Effect of race/ethnicity on risk of complete and partial molar pregnancy after adjustment for age. Gynecologic Oncology, 2016, 143, 73-76.	1.4	23
38	Using machine learning to create prognostic systems for endometrial cancer. Gynecologic Oncology, 2020, 159, 744-750.	1.4	23
39	Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 2021, 225, 237.e1-237.e24.	1.3	22
40	Minimally Invasive Radical Hysterectomy for Cervical Cancer: When Adoption of a Novel Treatment Precedes Prospective, Randomized Evidence. Journal of Clinical Oncology, 2019, 37, 3069-3074.	1.6	21
41	Trends in Use and Effect on Survival of Simple Hysterectomy for Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2019, 134, 1132-1143.	2.4	21
42	Association Between Overall Survival and the Tendency for Cancer Programs to Administer Neoadjuvant Chemotherapy for Patients With Advanced Ovarian Cancer. JAMA Oncology, 2021, 7, 1782.	7.1	21
43	Infection and extramural delivery with use of digoxin as a feticidal agent. Contraception, 2012, 85, 150-154.	1.5	20
44	Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old. Journal of Geriatric Oncology, 2018, 9, 516-519.	1.0	20
45	Effect of race/ethnicity on clinical presentation and risk of gestational trophoblastic neoplasia in patients with complete and partial molar pregnancy at a tertiary care referral center. American Journal of Obstetrics and Gynecology, 2016, 215, 334.e1-334.e6.	1.3	19
46	Changing treatment landscape for early cervical cancer: outcomes reported with minimally invasive surgery compared with an open approach. Current Opinion in Obstetrics and Gynecology, 2020, 32, 22-27.	2.0	19
47	Less radical surgery for early-stage cervical cancer: a systematic review. American Journal of Obstetrics and Gynecology, 2021, 224, 348-358.e5.	1.3	19
48	Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer. JAMA Network Open, 2020, 3, e2028612.	5.9	19
49	Outcomes of secondary cytoreductive surgery forÂpatients with platinum-sensitive recurrent ovarianÂcancer. American Journal of Obstetrics and Gynecology, 2019, 221, 625.e1-625.e14.	1.3	18
50	Case–control studies can be useful but have many limitations. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 23-23.	2.3	17
51	Adnexal Mass in the Postmenopausal Patient. Clinical Obstetrics and Gynecology, 2015, 58, 53-65.	1.1	16
52	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	1.4	16
53	Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research. Gynecologic Oncology, 2019, 152, 533-539.	1.4	16
54	The effect of guideline-concordant care in mitigating insurance status disparities in cervical cancer. Gynecologic Oncology, 2020, 159, 309-316.	1.4	16

ALEXANDER MELAMED

#	Article	IF	CITATIONS
55	Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes. Gynecologic Oncology, 2019, 155, 254-261.	1.4	15
56	Overuse of Cervical Cancer Screening Tests Among Women With Average Risk in the United States From 2013 to 2014. JAMA Network Open, 2021, 4, e218373.	5.9	15
57	Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. Gynecologic Oncology, 2017, 147, 612-616.	1.4	14
58	Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer. Gynecologic Oncology, 2018, 148, 168-173.	1.4	14
59	Obstetrician Volume as a Potentially Modifiable Risk Factor for Cesarean Delivery. Obstetrics and Gynecology, 2014, 124, 697-703.	2.4	13
60	Cesarean Delivery in Adolescents. Journal of Pediatric and Adolescent Gynecology, 2016, 29, 443-447.	0.7	13
61	The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis. Journal of Minimally Invasive Gynecology, 2021, 28, 537-543.	0.6	13
62	Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium. Obstetrics and Gynecology, 2015, 126, 815-822.	2.4	12
63	Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment. Gynecologic Oncology, 2018, 150, 406-411.	1.4	12
64	Outcomes of the First Pregnancy After Fertility-Sparing Surgery for Early-Stage Ovarian Cancer. Obstetrics and Gynecology, 2021, 137, 1109-1118.	2.4	12
65	Comparison of cervical mucus of 24/4 vs. 21/7 combined oral contraceptives. Contraception, 2012, 86, 710-715.	1.5	11
66	Palliative care referral patterns and measures of aggressive care at the end of life in patients with cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 66-72.	2.5	11
67	US Incidence of Late-Preterm Steroid Use and Associated Neonatal Respiratory Morbidity After Publication of the Antenatal Late Preterm Steroids Trial, 2015-2017. JAMA Network Open, 2022, 5, e2212702.	5.9	11
68	Association between peak estradiol levels and ovarian torsion among symptomatic patients receiving gonadotropin treatment. Journal of Assisted Reproduction and Genetics, 2017, 34, 627-631.	2.5	10
69	Chemotherapy, Radiation, or Combination Therapy for Stage III Uterine Cancer. Obstetrics and Gynecology, 2019, 134, 17-29.	2.4	10
70	Synthesis and biological evaluation of analogs of altohyrtin C (spongistatin 2). Tetrahedron, 2008, 64, 124-136.	1.9	9
71	BMD Reference Standards Among South Asians in the United States. Journal of Clinical Densitometry, 2010, 13, 379-384.	1.2	9
72	Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives. Contraception, 2013, 87, 732-737.	1.5	9

#	Article	IF	CITATIONS
73	Hospital volume and cesarean delivery among low-risk women in a nationwide sample. Journal of Perinatology, 2018, 38, 127-131.	2.0	9
74	Potential Consequences of Minimum-Volume Standards for Hospitals Treating Women With Ovarian Cancer. Obstetrics and Gynecology, 2019, 133, 1109-1119.	2.4	9
75	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, part I. Gynecologic Oncology, 2020, 158, 194-200.	1.4	9
76	Cost of care for the initial management of cervical cancer in women with commercial insurance. American Journal of Obstetrics and Gynecology, 2021, 224, 286.e1-286.e11.	1.3	9
77	Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Gynecologic Oncology, 2021, 162, 56-64.	1.4	9
78	Neoadjuvant chemotherapy for advanced stage endometrial cancer: A systematic review. Gynecologic Oncology Reports, 2021, 38, 100887.	0.6	9
79	Minimally invasive interval cytoreductive surgery: it's time for a randomized trial. International Journal of Gynecological Cancer, 2019, 29, 1339-1340.	2.5	8
80	Effect of regionalization of endometrial cancer care on site of care and patient travel. American Journal of Obstetrics and Gynecology, 2020, 222, 58.e1-58.e10.	1.3	8
81	Travel distance, hospital volume and their association with ovarian cancer short- and long-term outcomes. Gynecologic Oncology, 2020, 158, 415-423.	1.4	8
82	Trends in Place of Death Among Patients With Gynecologic Cancer in the United States. Obstetrics and Gynecology, 2018, 131, 1111-1120.	2.4	7
83	CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Gynecologic Oncology, 2019, 152, 568-573.	1.4	7
84	Employment disruption following the diagnosis of endometrial cancer. Gynecologic Oncology, 2021, 160, 199-205.	1.4	7
85	Association of Maryland Global Budget Revenue With Spending and Outcomes Related to Surgical Care for Medicare Beneficiaries With Cancer. JAMA Surgery, 2022, , e220135.	4.3	7
86	Clinical outcomes research in gynecologic oncology. Gynecologic Oncology, 2017, 146, 653-660.	1.4	6
87	Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection. Gynecologic Oncology, 2018, 149, 256-262.	1.4	6
88	Survival After Minimally Invasive Radical Hysterectomy for Early-stage Cervical Cancer. Obstetrical and Gynecological Survey, 2019, 74, 84-85.	0.4	6
89	Use of fertility preservation services in male reproductive-aged cancer patients. Gynecologic Oncology Reports, 2021, 36, 100716.	0.6	6
90	Facilitated cascade testing (FaCT): a randomized controlled trial. International Journal of Gynecological Cancer, 2021, 31, 779-783.	2.5	6

#	Article	IF	CITATIONS
91	Employment disruption among women with gynecologic cancers. International Journal of Gynecological Cancer, 2022, 32, 69-78.	2.5	6
92	Coronavirus Spectrum Infections (COVID-19, MERS, SARS) in Cancer Patients: A Systematic Review of the Literature. Cancer Investigation, 2020, 38, 436-444.	1.3	5
93	Patient reported outcomes measures in gynecologic oncology: A primer for clinical use, Part II. Gynecologic Oncology, 2020, 158, 201-207.	1.4	5
94	Use and outcomes of neoadjuvant chemotherapy for metastatic uterine cancer. Gynecologic Oncology, 2021, 162, 599-605.	1.4	5
95	The incidence of myelodysplastic syndrome in patients receiving poly-ADP ribose polymerase inhibitors for treatment of solid tumors: A meta-analysis Journal of Clinical Oncology, 2020, 38, 3641-3641.	1.6	5
96	Trends in the Use of Minimally Invasive Adnexal Surgery in the United States. Obstetrics and Gynecology, 2021, 138, 738-746.	2.4	5
97	Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncology, 2022, 8, 159.	7.1	5
98	The Effect of a Web-Based Cervical Cancer Survivor's Story on Parents' Behavior and Willingness to Consider Human Papillomavirus Vaccination for Daughters: Randomized Controlled Trial. JMIR Public Health and Surveillance, 2022, 8, e34715.	2.6	5
99	Patient Reported Outcomes: Recent Successes and Future Opportunities. Gynecologic Oncology, 2018, 148, 1-2.	1.4	4
100	Age-Associated Risk of 90-Day Postoperative Mortality After Cytoreductive Surgery for Advanced Ovarian Cancer. JAMA Surgery, 2019, 154, 669.	4.3	4
101	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. Gynecologic Oncology, 2020, 157, 329-334.	1.4	4
102	Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. International Journal of Gynecological Cancer, 2021, 31, 1341-1347.	2.5	4
103	Harnessing Minimally Invasive Surgery to Improve Outcomes in Endometrial Cancer Surgery—The Robots Are Coming. JAMA Surgery, 2019, 154, 539.	4.3	3
104	Variation in resource utilization associated with the surgical management of ovarian cancer. Gynecologic Oncology, 2019, 152, 587-593.	1.4	3
105	Trends in venous thromboembolism prophylaxis in gynecologic surgery for benign and malignant indications. Archives of Gynecology and Obstetrics, 2020, 302, 935-945.	1.7	3
106	Effects of U.S. Preventive Services Task Force (USPSTF) guidelines on cervical cancer screening, incidence, and mortality Journal of Clinical Oncology, 2018, 36, 1556-1556.	1.6	3
107	Long-term outcomes of vaginal hysterectomy for endometrial cancer. Gynecologic Oncology, 2021, ,	1.4	3
108	Role of tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: Systematic review and meta-analysis Gynecologic Oncology, 2022, , .	1.4	3

#	Article	IF	CITATIONS
109	A study design to identify associations. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1776-1776.	2.3	2
110	Toxicity after adjuvant therapy for stage III uterine cancer. Gynecologic Oncology, 2020, 159, 737-743.	1.4	2
111	Trends in ovarian conservation and association with survival in premenopausal patients with stage I leiomyosarcoma. Gynecologic Oncology, 2021, 161, 734-740.	1.4	2
112	Pathologic characteristics, patterns of care, and outcomes of Asian-Americans and Pacific islanders with uterine cancer. Gynecologic Oncology, 2022, 165, 160-168.	1.4	2
113	Electric Uterine Morcellation. JAMA - Journal of the American Medical Association, 2014, 312, 96.	7.4	1
114	482: Cesarean delivery in adolescent pregnancies. American Journal of Obstetrics and Gynecology, 2015, 212, S244-S245.	1.3	1
115	Dermoid Cyst Management and Pathologic Outcomes: A Review of Over 1,000 Cases at a Single Institution [9D]. Obstetrics and Gynecology, 2018, 131, 43S-43S.	2.4	1
116	Risk of Cesarean Delivery among Nulliparous Asian-Indian Women with Term Singleton Pregnancies. American Journal of Perinatology, 2019, 36, 335-340.	1.4	1
117	Time to accept a new old standard of care in cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1278-1279.	2.5	1
118	Placental cord insertion distance from the placental margin and its association with adverse perinatal outcomes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 255, 51-55.	1.1	1
119	Impact of clinical characteristics on human chorionic gonadotropin regression after molar pregnancy. Clinics, 2021, 76, e2830.	1.5	1
120	Adoption of minimally invasive surgery after neoadjuvant chemotherapy in women with metastatic uterine cancer. Gynecologic Oncology, 2022, 164, 341-347.	1.4	1
121	Laparoscopic Staging for Stage I Ovarian Cancer: An Analysis of the National Cancer Database. Gynecologic Oncology, 2015, 139, 593.	1.4	0
122	Safety of same day discharge in patients undergoing laparoscopic hysterectomy for endometrial intraepithelial neoplasia (EIN) and malignancy. Gynecologic Oncology, 2015, 136, 405-406.	1.4	0
123	Primary debulking surgery in advanced stage ovarian cancer is associated with improved survival. Gynecologic Oncology, 2015, 136, 403-404.	1.4	0
124	In Reply. Obstetrics and Gynecology, 2017, 130, 470-470.	2.4	0
125	All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer. Obstetrical and Gynecological Survey, 2017, 72, 713-715.	0.4	0
126	Reply. American Journal of Obstetrics and Gynecology, 2019, 221, 538.	1.3	0

#	Article	IF	CITATIONS
127	Potential survival benefits from optimized chemotherapy implementation in advanced ovarian cancer: Projections from a microsimulation model. PLoS ONE, 2019, 14, e0222828.	2.5	0
128	Case 18-2019: A 24-Year-Old Woman with a Pelvic Mass. New England Journal of Medicine, 2019, 380, 2361-2369.	27.0	0
129	Pregnancy after breast cancer: A population-based study of survival and obstetric outcomes Journal of Clinical Oncology, 2021, 39, e18783-e18783.	1.6	0
130	In Reply. Obstetrics and Gynecology, 2021, 138, 310-311.	2.4	0
131	Management of Ovarian Masses in the Older Woman. , 2016, , 1-10.		0
132	Management of Ovarian Masses in the Older Woman. , 2017, , 549-558.		0
133	Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all-cause mortality Journal of Clinical Oncology, 2017, 35, 5537-5537.	1.6	0
134	National patterns and factors predicting employment disruption in women diagnosed with endometrial cancer Journal of Clinical Oncology, 2020, 38, e18093-e18093.	1.6	0
135	Trends in human papillomavirus vaccination among women aged 27 to 45 years, from 2017 to 2019. American Journal of Obstetrics and Gynecology, 2022, 226, 568-570.e1.	1.3	0
136	Efficacy of a password-protected, pill-dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery Journal of Clinical Oncology, 2022, 40, 12019-12019.	1.6	0
137	Sentinel lymph node biopsy utilization in early-stage vulvar cancer: A National Cancer Database Study Journal of Clinical Oncology, 2022, 40, e17536-e17536.	1.6	0
138	Efficacy of a passwordâ€protected, pillâ€dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. Cancer, 0, , .	4.1	0